An interventional study of PVAC GOLD multielectrode catheter and Contact Force single-tip ablation catheter in Atrial Fibrillation, sponsored by L.V.A. Boersma. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-23.
Sponsored by L.V.A. Boersma · Not applicable, Interventional, and Treatment
The GOLD FORCE trial investigates the differences between treatment with a Contact Force single-tip catheter against the PVAC GOLD multielectrode catheter in cardiac ablation procedures in patients with paroxysmal atrial fibrillation.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's enrollment of 212 is above the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →L.V.A. Boersma is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
History of symptomatic paroxysmal atrial fibrillation defined as:
AF symptoms defined as the manifestation of any of the following:
Exclusion Criteria:
Structural heart disease of clinical significance including:
Regular AF-ablation with a multi-electrode ablation catheter
Device: PVAC GOLD multielectrode catheter
Regular AF-ablation with a regular Contact Force single-tip ablation catheter
Device: Contact Force single-tip ablation catheter
Cardiac ablation for Atrial Fibrillation
Number of participants free of Atrial Fibrillation and not taking anti-arrhythmic drugs
Time frame: Month 3 after intervention
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
L.V.A. Boersma